Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07268586

Enrollment

158

Registered

2025-12-08

Start date

2025-08-01

Completion date

2026-02-28

Last updated

2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

Atropine, Inferior ST elevation myocardial infarction

Brief summary

People with acute inferior wall myocardial infarction will be given an intravenous drug called atropine that increases the heart rate to check if it prevents heart rhythm disturbances during performing coronary intervention

Interventions

DRUGIntravenous atropine immediately before wire crossing during primary percutaneous coronary intervention

Intravenous atropine 1 mg immediately before wire crossing during primary percutaneous coronary intervention

DRUGIntravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention

Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Acute inferior ST elevation myocardial infarction

Exclusion criteria

* Execution of rescur percutaneous coronary intervention after thrombolysis * Mechanical complications or no reflow or spontaneous reperfusion. * Prior implantation of permanent or temporary pacemakers * History of bradycardia, hypotension or ventricular tachycardia with a definitive cause (unrelated to the disease under study) * Prior coronary artery bypass graft surgery * Atropine contraindications Unwillingness to participate in the

Design outcomes

Primary

Measure	Time frame	Description
Conduction abnormalities	Periprocedurally	Occurrence of conduction abnormalities
Reperfusion arrhythmias	Periprocedurally	Occurrence of reperfusion arrhythmias

Secondary

Measure	Time frame	Description
Major adverse cardiac events	Periprocedurally	Inhospital major adverse cardiac events including all-cause mortality, cardiovascular mortality, stroke and myocardial infarction

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026